It is currently Sat Nov 01, 2014 2:02 am

News News of Gilenya

Site map of Gilenya » Forum : Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Novartis investigating death possibly linked to Gilenya

Image

One year after Novartis won FDA approval for a new type of drug to treat relapsing forms of multiple sclerosis and delay the progression of physical disabilities, the drugmaker is now investigating a death tied to its pill, which is called Gilenya. The disclosure, which was made by a Wall Street analyst, has the potential to cast a pall over a drug that has been expected to generate blockbuster sales.

Specifically, this is the ...
Read more : Novartis investigating death possibly linked to Gilenya | Views : 1278 | Replies : 0


Anger at NICE oral MS drug Gilenya decision

Image

Campaigners have condemned a decision that could lead to a ban on the use of the first pill to treat multiple sclerosis.

The National Institute of Health and Clinical Excellence (NICE) ruled the drug was too expensive following a second consultation on its use.

It says it is not minded to make it available on the NHS but a final decision has not been made yet and people can still make their views known. ...
Read more : Anger at NICE oral MS drug Gilenya decision | Views : 1301 | Replies : 0


Actual details on reduced Lymphocytes count?

I tried doing a search to find the actual numeric effects on cell counts of circulating Lymphocytes before and after being on Gilenya. I didn't find it. The best I found was an approximation for mice in an experiment, who I would assume would of been on much more severe doses.

I would love to see the data from the Phase II and Phase III trials; which used different dosages? Is this data available anywhere? ...
Read more : Actual details on reduced Lymphocytes count? | Views : 1384 | Replies : 3


Gilenya fails to win NICE backing in draft guidance

Image

The UK's health cost body National Institute for Health and Clinical Excellence, or NICE, in its revised draft guidance did not recommend Swiss pharmaceutical giant Novartis' multiple sclerosis pill Gilenya, as it believes the drug would not be cost effective for the National Health Service, or NHS, in comparison with other available treatments. NICE has not yet issued guidance for the NHS.

Gilenya, or fingolimod, is a daily capsule that could reduce relapses in ...
Read more : Gilenya fails to win NICE backing in draft guidance | Views : 1062 | Replies : 0


Day 4 on Gilenya

I started Gilenya on Saturday. I don't know what I was expecting. I was a little fatigued the first couple of days. Other than that nothing has happened, good or bad. Just a not for anyone interested in starting.
Read more : Day 4 on Gilenya | Views : 3486 | Replies : 4


My experiences, now on Gilenya

First a little context / history.

I have had 3 CCSVI procedures, with little to no relief. I have tried ABX's, I was initially on REBIF, which failed for me. I have had MS Symptoms for around 15 years, with a diagnosis of MS for the past 8 years. I have two neurologists, with one saying SPMS, and the other saying RR. My EDSS is about 4.0 or higher. I can walk just over 1km. ...
Read more : My experiences, now on Gilenya | Views : 3880 | Replies : 3


Gilenya and LDN

Hi, to the forum:

Has anyone been thinking of taking both Gilenya and LDN?
Does anyone know if there are contraindications?
What a dilemma*
I would love to talk about it

Regards everyone.
Read more : Gilenya and LDN | Views : 4091 | Replies : 3


Gilenya® shows up to 71% reduction in relapse rates

Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates

Image

Novartis will showcase data from 13 abstracts on fingolimod (Gilenya®), at the 5th Joint Triennial Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) taking place from 19-22 October in Amsterdam.

The data being presented for fingolimod at ECTRIMS/ACTRIMS highlight the Novartis clinical trial program for ...
Read more : Gilenya® shows up to 71% reduction in relapse rates | Views : 1012 | Replies : 0


Japan approves Novartis’ oral MS drug Gilenya

Image

Japanese regulatory authorities have approved Novartis’ once-daily multiple sclerosis (MS) drug Gilenya.

The Gilenya sanction covers use of the drug for preventing relapse and delaying progression of physical disability in adult MS patients.

The only other drug licensed in Japan for preventing relapse of MS patients is interferon beta. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
Read more : Japan approves Novartis’ oral MS drug Gilenya | Views : 864 | Replies : 0


Gilenya, may increase risk of macular edema in some patients

Image


The first U.S. Food and Drug Administration-approved oral medication for multiple sclerosis poses a potential risk of macular edema, particularly in patients with a history of uveitis, according to a neuro-ophthalmologist.

MS patients who receive Gilenya (fingolimod, Novartis) should undergo baseline and follow-up examinations 3 to 4 months after initiation of treatment, Robert C. Sergott, MD, said at the Wills Eye Institute Alumni Conference in Philadelphia.

“The macular edema issue is one that we ...
Read more : Gilenya, may increase risk of macular edema in some patients | Views : 1780 | Replies : 1


 

Login  •  Register


Statistics

Total posts 221023 • Total topics 22917 • Total members 14474


Contact us | Terms of Service